The host immune response in respiratory virus infection: balancing virus clearance and immunopathology

Amy H Newton, Amber Cardani, Thomas J Braciale, Amy H Newton, Amber Cardani, Thomas J Braciale

Abstract

The respiratory tract is constantly exposed to the external environment, and therefore, must be equipped to respond to and eliminate pathogens. Viral clearance and resolution of infection requires a complex, multi-faceted response initiated by resident respiratory tract cells and innate immune cells and ultimately resolved by adaptive immune cells. Although an effective immune response to eliminate viral pathogens is essential, a prolonged or exaggerated response can damage the respiratory tract. Immune-mediated pulmonary damage is manifested clinically in a variety of ways depending on location and extent of injury. Thus, the antiviral immune response represents a balancing act between the elimination of virus and immune-mediated pulmonary injury. In this review, we highlight major components of the host response to acute viral infection and their role in contributing to mitigating respiratory damage. We also briefly describe common clinical manifestations of respiratory viral infection and morphological correlates. The continuing threat posed by pandemic influenza as well as the emergence of novel respiratory viruses also capable of producing severe acute lung injury such as SARS-CoV, MERS-CoV, and enterovirus D68, highlights the need for an understanding of the immune mechanisms that contribute to virus elimination and immune-mediated injury.

Keywords: Inflammatory response; Influenza; Lungs; Respiratory infection; Virus.

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Molinari NA, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–96. doi: 10.1016/j.vaccine.2007.03.046.
    1. Herold S, et al. Apoptosis signaling in influenza virus propagation, innate host defense, and lung injury. J Leukoc Biol. 2012;92(1):75–82. doi: 10.1189/jlb.1011530.
    1. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev. 2013;255(1):25–39. doi: 10.1111/imr.12101.
    1. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778–809. doi: 10.1128/CMR.14.4.778-809.2001.
    1. Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 2015;15(4):231–42. doi: 10.1038/nri3806.
    1. Coro ES, Chang WL, Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol. 2006;176(7):4343–51. doi: 10.4049/jimmunol.176.7.4343.
    1. Zhou Z, et al. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol. 2007;81(14):7749–58. doi: 10.1128/JVI.02438-06.
    1. Okabayashi T, et al. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 2011;160(1–2):360–6. doi: 10.1016/j.virusres.2011.07.011.
    1. Jewell NA, et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol. 2010;84(21):11515–22. doi: 10.1128/JVI.01703-09.
    1. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005;175(6):3463–8. doi: 10.4049/jimmunol.175.6.3463.
    1. Teijaro JR. The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options. Curr Top Microbiol Immunol. 2015;386:3–22.
    1. Horiuchi T, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010;49(7):1215–28. doi: 10.1093/rheumatology/keq031.
    1. Souza LM, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232(4746):61–5. doi: 10.1126/science.2420009.
    1. Unkel B, et al. Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. J Clin Invest. 2012;122(10):3652–64. doi: 10.1172/JCI62139.
    1. Huang FF, et al. GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med. 2011;184(2):259–68. doi: 10.1164/rccm.201012-2036OC.
    1. Shibata Y, et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 2001;15(4):557–67. doi: 10.1016/S1074-7613(01)00218-7.
    1. Mukaida N. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol. 2000;72(4):391–8.
    1. Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. Eur J Immunol. 2008;38(8):2168–79. doi: 10.1002/eji.200838155.
    1. Ichikawa A, et al. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am J Respir Crit Care Med. 2013;187(1):65–77. doi: 10.1164/rccm.201203-0508OC.
    1. Wang W, et al. Monoclonal antibody against CXCL-10/IP-10 ameliorates influenza A (H1N1) virus induced acute lung injury. Cell Res. 2013;23(4):577–80. doi: 10.1038/cr.2013.25.
    1. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702. doi: 10.1146/annurev-immunol-032713-120145.
    1. Tekkanat KK, et al. RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease. Eur J Immunol. 2002;32(11):3276–84. doi: 10.1002/1521-4141(200211)32:11<3276::AID-IMMU3276>;2-5.
    1. Tyner JW, et al. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med. 2005;11(11):1180–7. doi: 10.1038/nm1303.
    1. Schutte BC, McCray PB., Jr [beta]-defensins in lung host defense. Annu Rev Physiol. 2002;64:709–48. doi: 10.1146/annurev.physiol.64.081501.134340.
    1. Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci. 2005;62(22):2576–87. doi: 10.1007/s00018-005-5372-0.
    1. Zhu J, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell. 2002;111(6):867–78. doi: 10.1016/S0092-8674(02)01141-8.
    1. Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012;24(2):126–35. doi: 10.5021/ad.2012.24.2.126.
    1. Vareille M, et al. The airway epithelium: soldier in the fight against respiratory viruses. Clin Microbiol Rev. 2011;24(1):210–29. doi: 10.1128/CMR.00014-10.
    1. Xu W, et al. Role of epithelial nitric oxide in airway viral infection. Free Radic Biol Med. 2006;41(1):19–28. doi: 10.1016/j.freeradbiomed.2006.01.037.
    1. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med. 2010;61:105–19. doi: 10.1146/annurev.med.60.041807.123500.
    1. Hartshorn KL. Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense. Front Biosci (Schol Ed) 2010;2:527–46. doi: 10.2741/s83.
    1. Arnold R, Konig W. Respiratory syncytial virus infection of human lung endothelial cells enhances selectively intercellular adhesion molecule-1 expression. J Immunol. 2005;174(11):7359–67. doi: 10.4049/jimmunol.174.11.7359.
    1. Short KR, et al. Influenza virus and endothelial cells: a species specific relationship. Front Microbiol. 2014;5:653. doi: 10.3389/fmicb.2014.00653.
    1. Hallin GW, et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med. 1996;24(2):252–8. doi: 10.1097/00003246-199602000-00012.
    1. Short KR, et al. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014;14(1):57–69. doi: 10.1016/S1473-3099(13)70286-X.
    1. Teijaro JR, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146(6):980–91. doi: 10.1016/j.cell.2011.08.015.
    1. Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol. 2014;14(2):81–93. doi: 10.1038/nri3600.
    1. Goritzka M, et al. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. J Exp Med. 2015;212(5):699–714. doi: 10.1084/jem.20140825.
    1. Pulendran B, Maddur MS. Innate immune sensing and response to influenza. Curr Top Microbiol Immunol. 2015;386:23–71.
    1. Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med. 2013;210(7):1283–99. doi: 10.1084/jem.20122220.
    1. Kruger P, et al. Neutrophils: between host defence, immune modulation, and tissue injury. PLoS Pathog. 2015;11(3):e1004651. doi: 10.1371/journal.ppat.1004651.
    1. Snelgrove RJ, et al. An absence of reactive oxygen species improves the resolution of lung influenza infection. Eur J Immunol. 2006;36(6):1364–73. doi: 10.1002/eji.200635977.
    1. Shornick LP, et al. Airway epithelial versus immune cell Stat1 function for innate defense against respiratory viral infection. J Immunol. 2008;180(5):3319–28. doi: 10.4049/jimmunol.180.5.3319.
    1. Matute-Bello G, et al. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;156(6):1969–77. doi: 10.1164/ajrccm.156.6.96-12081.
    1. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159–75. doi: 10.1038/nri3399.
    1. Monticelli LA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol. 2011;12(11):1045–54. doi: 10.1038/ni.2131.
    1. Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology. 2009;128(2):151–63. doi: 10.1111/j.1365-2567.2009.03167.x.
    1. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol. 2013;31:163–94. doi: 10.1146/annurev-immunol-032712-100001.
    1. Abboud G et al (2015) Natural killer cells and innate IFN-gamma participate in host defense against respiratory vaccinia virus infection. J Virol
    1. Kos FJ, Engleman EG. Role of natural killer cells in the generation of influenza virus-specific cytotoxic T cells. Cell Immunol. 1996;173(1):1–6. doi: 10.1006/cimm.1996.0245.
    1. Li F, et al. Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection. J Virol. 2012;86(4):2251–8. doi: 10.1128/JVI.06209-11.
    1. Kumar P, et al. IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol. 2013;6(1):69–82. doi: 10.1038/mi.2012.49.
    1. Gottschalk C, Mettke E, Kurts C. The role of invariant natural killer T cells in dendritic cell licensing, cross-priming, and memory CD8(+) T cell generation. Front Immunol. 2015;6:379.
    1. Juno JA, Keynan Y, Fowke KR. Invariant NKT cells: regulation and function during viral infection. PLoS Pathog. 2012;8(8):e1002838. doi: 10.1371/journal.ppat.1002838.
    1. Born WK, et al. Role of gammadelta T cells in protecting normal airway function. Respir Res. 2000;1(3):151–8. doi: 10.1186/rr26.
    1. Poccia F, et al. Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells. J Infect Dis. 2006;193(9):1244–9. doi: 10.1086/502975.
    1. Dodd J, et al. Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease. J Immunol. 2009;182(2):1174–81. doi: 10.4049/jimmunol.182.2.1174.
    1. Simonian PL, et al. Gammadelta T cells protect against lung fibrosis via IL-22. J Exp Med. 2010;207(10):2239–53. doi: 10.1084/jem.20100061.
    1. Neyt K, Lambrecht BN. The role of lung dendritic cell subsets in immunity to respiratory viruses. Immunol Rev. 2013;255(1):57–67. doi: 10.1111/imr.12100.
    1. Guilliams M, Lambrecht BN, Hammad H. Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections. Mucosal Immunol. 2013;6(3):464–73. doi: 10.1038/mi.2013.14.
    1. Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol. 2012;12(4):295–305. doi: 10.1038/nri3166.
    1. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med. 2006;203(5):1153–9. doi: 10.1084/jem.20052359.
    1. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11(11):762–74. doi: 10.1038/nri3070.
    1. Chen J, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289–301. doi: 10.1128/JVI.01281-09.
    1. Herati RS, et al. Circulating CXCR5+ PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J Immunol. 2014;193(7):3528–37. doi: 10.4049/jimmunol.1302503.
    1. Alper CM, et al. Prechallenge antibodies: moderators of infection rate, signs, and symptoms in adults experimentally challenged with rhinovirus type 39. Laryngoscope. 1996;106(10):1298–305. doi: 10.1097/00005537-199610000-00025.
    1. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59(1–3):118–28. doi: 10.1007/s12026-014-8534-z.
    1. Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318–25. doi: 10.1128/JVI.01049-10.
    1. Moskophidis D, Kioussis D. Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med. 1998;188(2):223–32. doi: 10.1084/jem.188.2.223.
    1. Graham BS, et al. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest. 1991;88(3):1026–33. doi: 10.1172/JCI115362.
    1. Kennedy JL, et al. Pathogenesis of rhinovirus infection. Curr Opin Virol. 2012;2(3):287–93. doi: 10.1016/j.coviro.2012.03.008.
    1. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. 2008;3:499–522. doi: 10.1146/annurev.pathmechdis.3.121806.154316.
    1. Hwang DM, et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005;18(1):1–10. doi: 10.1038/modpathol.3800247.
    1. (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3):531–7
    1. Josset L, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio. 2013;4(3):e00165–13. doi: 10.1128/mBio.00165-13.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere